Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03778957 · ClinicalTrials.gov registry record · Phase 3
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
A Phase 3 study of Hepatocellular Carcinoma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 724
- Enrollment target
- 20
- Study locations
NCT03778957: Active Phase 3 study of Hepatocellular Carcinoma, sponsored by AstraZeneca.
NCT03778957 is a Phase 3 study of Hepatocellular Carcinoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 724 participants, above the 252-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (187% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03778957, a Phase 3 study of Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 724 participants
- Enrollment target
- 20
- Study locations
Study Summary
A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma
Primary Outcome
PFS per Blinded Independent Central Review (BICR) assessment will be defined as the time from the date of randomization until the date of first objective disease progression or death
Conditions Studied
Interventions
- DRUG Bevacizumab
- OTHER Placebo
- DRUG Durvalumab
- PROCEDURE Transarterial Chemoembolization (TACE)
Study Locations (20)
California
- Research Site - Costa Mesa
- Research Site - La Jolla
- Research Site - Orange
Florida
- Research Site - Jacksonville
- Research Site - Miami
District of Columbia
- Research Site - Washington D.C.
Hawaii
- Research Site - Honolulu
Illinois
- Research Site - Chicago
Louisiana
- Research Site - Shreveport
Michigan
- Research Site - Detroit
Minnesota
- Research Site - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 724 participants |
| Start Date | 2018-11-30 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 3 |
What the registry record for NCT03778957 still lists
NCT03778957 is an interventional study that assigns participants to a tested intervention. The registered 724 participants enrollment target is mid-sized for trials with a published cap, above the 252-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (187% higher).
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT03778957 names 20 study sites across 17 states, led by California, Florida, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT03778957 about?
NCT03778957 is a clinical study titled "A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma". A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma
What is the current status of trial NCT03778957?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 724 participants. The study started on 2018-11-30. Estimated completion is 2026-08-31.
What conditions does trial NCT03778957 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT03778957?
The interventions under investigation include: Bevacizumab (DRUG), Placebo (OTHER), Durvalumab (DRUG), Transarterial Chemoembolization (TACE) (PROCEDURE).
Who is sponsoring clinical trial NCT03778957?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03778957 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Hawaii, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03778957's enrollment target sits among peer trials
724 17th of 145 higher than 129 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
RECRUITING · Phase 3
-
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RECRUITING · Phase 3
-
Evaluating Novel Therapies in ctDNA Positive GI Cancers
RECRUITING · Phase 3
-
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
ACTIVE NOT RECRUITING · Phase 3
-
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06664619 · 724 participants · Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
- NCT05634967 · 725 participants
Kesimpta (Ofatumumab) Pregnancy Registry
- NCT06641466 · 723 participants · Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
- NCT07088068 · 723 participants · Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI